Which Weight Loss Injection Works Best in 2026 ?

This updated comparison looks at the very latest trial results, the real-world cost picture and what treatments mean in terms of safety, results, and personal clinical support. Whether you are considering starting treatment for the first time or thinking about switching, the 2026 picture is more nuanced — and more interesting — than ever.

For the past two years, the weight loss injection debate in the UK has largely followed a familiar script: Mounjaro is more powerful, Wegovy is the established option, and the choice between them comes down to clinical suitability and budget. But in January 2026, that script was rewritten. The MHRA approved a new higher dose of Wegovy — 7.2mg weekly — making the UK the first country in the world to do so. Suddenly, the gap between the two treatments looks very different.

How Do They Work? A Quick Recap

Both Mounjaro and Wegovy are weight loss injections administered once weekly via a pre-filled pen. Both are MHRA-approved and NICE-endorsed for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition.

Wegovy contains semaglutide, a GLP-1 receptor agonist. It mimics a gut hormone released after eating, signalling to the brain that the body is full, slowing gastric emptying, and reducing appetite. It is manufactured by Novo Nordisk and has been available in the UK since 2023.

Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist — sometimes called a 'twincretin'. By acting on two appetite-regulating hormonal pathways simultaneously, it produces a broader and in most patients more powerful metabolic effect. It was also approved by the MHRA in 2023 and is manufactured by Eli Lilly.

The key distinction, then, is mechanism depth. One pathway versus two. And for a long time, that translated into measurably different results in clinical trials.

The Latest Trial Results: What the Evidence Says in 2026

SURMOUNT-1 and STEP 1: The Foundational Trials

The foundational efficacy data for both treatments comes from separate large-scale randomised controlled trials. The STEP 1 trial, published in the New England Journal of Medicine in 2021, found that participants on semaglutide 2.4mg lost an average of 14.9% of their body weight over 68 weeks, with around 69% achieving at least 10% weight loss. The SURMOUNT-1 trial, published in 2022, showed that tirzepatide at 5mg, 10mg, and 15mg doses produced average weight loss of 15%, 19.5%, and 20.9% respectively over 72 weeks — substantially higher than anything seen with semaglutide at comparable timepoints.

SURMOUNT-5: The First Head-to-Head Trial

The most clinically significant piece of evidence comparing these two treatments directly is the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025. This was the first randomised controlled head-to-head trial comparing tirzepatide directly with semaglutide for weight loss. At their then-standard maximum doses — Mounjaro 15mg versus Wegovy 2.4mg — tirzepatide produced an average weight loss of 20.2% of body weight, compared to 13.7% with semaglutide over 72 weeks. Around 45% of Mounjaro participants achieved at least 25% weight loss, versus just 19% of Wegovy participants.

It is worth noting that SURMOUNT-5 was funded by Eli Lilly and conducted as an open-label trial. It also tested Wegovy only at the then-maximum dose of 2.4mg — the higher dose approved in January 2026 was not yet available. These are important context points when interpreting the results.

The 2026 Game-Changer: Wegovy 7.2mg and the STEP UP Trial

On 12th January 2026, the MHRA approved a new 7.2mg dose of Wegovy, based on data from the STEP UP trial. The UK became the first country in the world to grant this approval, ahead of the US FDA. The STEP UP trial enrolled 1,407 adults with obesity and found that patients on 7.2mg weekly semaglutide lost an average of 20.7% of their body weight over 72 weeks — compared to 17.5% on the standard 2.4mg dose. Significantly, one in three participants on the higher dose achieved 25% or more weight loss, a threshold previously associated only with bariatric surgery and the highest Mounjaro dose.

The result: at their respective highest approved doses, Mounjaro (20.2%) and Wegovy 7.2mg (20.7%) are now essentially equivalent in terms of average weight loss outcomes. The gap that once defined this debate has, for most patients, closed.

Key Clinical Trial Results at a Glance

Sources: SURMOUNT-1 (NEJM 2022); SURMOUNT-5 (NEJM 2025); STEP 1 (NEJM 2021); STEP UP trial / MHRA approval January 2026. Discontinuation figures from SURMOUNT-5. Note: SURMOUNT-5 compared Mounjaro 15mg vs Wegovy 2.4mg only. Highest-dose row reflects separate trials with different populations.

Safety and Side Effects: What to Expect

Both weight loss injections share a broadly similar side effect profile, given that they operate on overlapping hormonal pathways. Gastrointestinal symptoms — including nausea, vomiting, and digestive discomfort — are the most commonly reported effects, particularly during the dose titration phase as the body adjusts. For the vast majority of patients, these effects are transient and manageable with appropriate clinical guidance.

Where the treatments do differ is in tolerability data from the SURMOUNT-5 trial. Discontinuation due to gastrointestinal events was 2.7% for tirzepatide versus 5.6% for semaglutide in that trial — suggesting Mounjaro may be somewhat better tolerated at standard doses, despite its greater potency. That said, individual responses vary considerably, and the best-tolerated treatment is always the one that is right for the individual patient — which is why personal clinical assessment is so important.

One additional consideration unique to Mounjaro is a potential interaction with oral medications that rely on consistent gastric absorption rates, including the oral contraceptive pill. Patients on Mounjaro are advised to use additional contraceptive precautions during dose escalation. This is not a reason to avoid the treatment, but it is a reason to have a thorough clinical consultation before starting.

Sources: SURMOUNT-5 (NEJM 2025); MHRA product information for tirzepatide and semaglutide; NHS guidance on GLP-1 receptor agonists 2026.

Cost and Affordability in 2026: The Picture Has Shifted

Until September 2025, Mounjaro was the more cost-competitive option at several dose levels. That changed when Eli Lilly increased UK prices — in some cases by as much as 170% for a month's supply at the maintenance dose, according to BBC reporting at the time. Wegovy's pricing, whilst not cheap, has remained more stable by comparison.

The arrival of Wegovy 7.2mg complicates the picture further. At the highest doses, both treatments now cost roughly £279 to £350 per month, making them broadly comparable in price whilst delivering comparable results. For patients who achieve their therapeutic goals at Wegovy's standard 2.4mg dose, however, the cost difference remains meaningful.

Prices are indicative private prescription costs and vary by provider. NHS access is limited to eligible patients meeting strict NICE TA criteria.

For patients focused on long-term affordability, Wegovy at standard doses remains the more accessible option financially. For those who need — or respond better to — the higher doses, the price differential largely disappears. The right financial decision is therefore inseparable from the right clinical decision, which again underscores the value of personalised support from a regulated provider.

Which Treatment Is Right for You?

This is not a question with a universal answer — and any provider that suggests otherwise is not providing genuine clinical care. Both Mounjaro and Wegovy are effective, MHRA-approved, regulated weight loss injections with strong clinical evidence behind them. The right choice for an individual depends on a combination of factors that only a proper consultation can establish.

Why Choosing a Trusted, Regulated Online Pharmacy Matters

With demand for weight loss injections at an all-time high, the UK market has unfortunately attracted unregulated sellers operating via social media and unverified online channels. The MHRA and NHS England have both issued warnings about the risks of obtaining GLP-1 medications without clinical oversight — including the risk of counterfeit products, incorrect dosing, and dangerous side effects without appropriate support.

Happy Pharmacy is a GPhC-registered online pharmacy with a TrustPilot rating of 4.8 out of 5, built entirely on real patient feedback. Every patient journey begins with a genuine clinical consultation carried out by a registered prescriber who assesses your medical history, current medications, BMI, and health goals. Treatment is only offered where it is clinically appropriate — and that standard never changes.

Happy Pharmacy provides access to both Mounjaro and Wegovy through a regulated, personal, and fully supported online service. There are no automated pathways, no one-size-fits-all protocols, and no corners cut on safety. From first consultation through to ongoing monitoring, the focus is on results that are safe, sustainable, and right for you as an individual.

Blog medically reviewed by : Nigel Howard, GPhC Registered Prescriber, 14 May 2026

References

1 New England Journal of Medicine..Once-weekly semaglutide in adults with overweight or obesity (STEP 1).

2. New England Journal of Medicine. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1).

3. New England Journal of Medicine. Tirzepatide vs semaglutide for treatment of obesity (SURMOUNT-5). 

4. MHRA. Authorisation of Wegovy 7.2mg (semaglutide) for weight management. MHRA, January 2026. 

5. STEP UP trial data — Novo Nordisk (2025/2026). Efficacy and Safety of Semaglutide 7.2mg in Obesity. 

6. NICE. Technology Appraisal TA1026: Tirzepatide for managing obesity and overweight in adults. 

7. NHS England (2026). Interim commissioning guidance: Mounjaro for obesity management

8. UCL / BMC Medicine (2026). GLP-1 medication use in the UK: prevalence and market analysis